文献速递炎症性肠病肝病

临床试验:炎症性肠病患者局部涂抹咪喹莫特后皮内接种乙型肝炎疫苗与肌内接种乙型肝炎疫苗的比较

Clinical trial: intra dermal hepatitis B vaccination with topical imiquimod versus intra muscular hepatitis B vaccination in patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2022-05-11

本研究将104例无乙型肝炎感染或免疫证据的成人炎症性肠病患者按1:1随机分组,分别接受注射部位局部涂抹咪喹莫特后皮内接种乙型肝炎疫苗(ID-Imq组,53例)或涂抹水性乳膏后肌内接种(IM-Aq组),在第0、1、6个月接种。12个月时ID-Imq组血清保护率显著高于IM-Aq组(91% vs 69%;OR 4.39,95%CI 1.47-13.11)。结论认为皮内接种联合局部咪喹莫特预处理安全,且血清保护优于常规肌内接种。

要点

  • 12个月血清保护率ID-Imq组91% vs IM-Aq组69%,OR 4.39(95%CI 1.47-13.11)。
  • 多因素分析显示皮内疫苗联合局部咪喹莫特及较高白蛋白水平与更高血清保护率相关。
  • 两组安全性相似,但ID-Imq组局部反应更常见。

核心结论

  • 在炎症性肠病患者中,局部涂抹咪喹莫特后皮内接种乙型肝炎疫苗安全,且血清保护优于常规肌内接种。

研究设计与样本

  • 随机、患者与研究者双盲对照试验,104例无乙型肝炎感染或免疫证据的成人炎症性肠病患者按1:1随机分组,ID-Imq组53例。

主要发现

  • 12个月血清保护率ID-Imq组91% vs IM-Aq组69%(OR 4.39,95%CI 1.47-13.11)。
  • 随机分组时使用类固醇、免疫调节剂或生物制剂的患者比例分别为15%、55%或22%。
  • 多因素分析显示皮内疫苗联合局部咪喹莫特及较高白蛋白水平与更高血清保护率相关。
  • 两组安全性相似,但ID-Imq组局部反应更常见。

关键数值与推荐

  • 主要终点为12个月血清保护率,定义为抗-HBs ≥10 mIU/ml的受试者百分比。
  • 于第0、1、6个月接种乙型肝炎疫苗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Efficacy with conventional intra muscular (IM) hepatitis B vaccination in patients with inflammatory bowel disease (IBD) is suboptimal. AIM: To compare the immunogenicity of intradermal (ID) hepatitis B vaccination after topical imiquimod pre-treatment with IM hepatitis B vaccination in patients with IBD. METHODS: Adult IBD patients with no evidence of hepatitis B infection or immunity (negative to HBsAg/anti-HBc/anti-HBs) were randomised 1:1 to receive either ID hepatitis B vaccine with topical imiquimod pre-treatment to injection site (ID-Imq) or IM hepatitis B vaccine with aqueous cream pre-treatment (IM-Aq) at 0, 1 and 6 months. Patients and investigators were blinded to the randomisation and intervention. The primary endpoint was seroprotection rate at 12-month, defined as percentage of subjects with anti-HBs ≥10 mIU/ml. RESULTS: Between September 2019 and December 2020, 104 patients with IBD (68% male; 50% Crohn's) enrolled, and 53 assigned to ID-Imq group. The percentage of patients using steroids, immunomodulators or biologics at randomisation was 15%, 55% or 22%, respectively. Seroprotection rate at 12 months was significantly higher in the ID-Imq group than the IM-Aq group (91% vs 69%; OR 4.39, 95% CI 1.47-13.11). Multivariate analysis showed that ID vaccine with topical imiquimod and higher albumin level were associated with a higher seroprotection rate. The safety profile was similar but local reactions were more common in the ID-Imq group. CONCLUSIONS: Intradermal hepatitis B vaccination with topical imiquimod pre-treatment is safe and offers superior seroprotection to conventional IM administration in patients with IBD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ko KL, Lam YF, Cheung KS, et al. Clinical trial: intra dermal hepatitis B vaccination with topical imiquimod versus intra muscular hepatitis B vaccination in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022. PMID: 35546255. doi:10.1111/apt.16970

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。